Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic

JOURNAL OF THE NEUROLOGICAL SCIENCES

卷:429

Article

Bringeland, Gerd Haga^1,2  Blaser, Nello^3,4  Myhr, Kjell-Morten^1,2  Vedeler, Christian Alexander^1,2  Gavasso, Sonia^1,2 

[1] Haukeland Hosp, Dept Neurol, Neuro SysMed, Bergen, Norway

[2] Univ Bergen, Dept Clin Med, Bergen, Norway

[3] Univ Bergen, Dept Informat, Bergen, Norway

[4] Univ Bergen, Ctr Data Sci, CEDAS, Bergen, Norway

关键词: Multiple sclerosis;    Natalizumab;    Wearing-off;    Extended interval dosing;    Receptor occupancy;    Individualized medicine;   

DOI  :  10.1016/j.jns.2021.117622

来源: Elsevier

【 摘 要 】

Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis, but many treated patients report subjective wearing-off symptoms at the end of the 4-week interval between infusions. Extended interval dosing (EID) is a promising strategy to mitigate the risk of natalizumab-associated progressive multifocal leukoencephalopathy, but it is unknown whether EID affects wearing-off symptoms. In this observational study, we evaluated if prevalence or intensity of wearing-off symptoms changed when natalizumab dosing intervals were extended from 4 to 6 weeks in 30 treated patients during the outbreak of COVID-19 in Norway. New or increased wearing-off symptoms during EID were reported by 50%. Symptom increase was more frequent among patients with pre-existing wearing-off symptoms during standard dosing compared to patients without such preexisting symptoms [p = 0.0005]. Our observations support the need to study the effect of EID on wearing-off symptoms in randomized controlled trials.

【 授权许可】

Free